Study of a RAS-targeting pill for lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new daily pill (daraxonrasib/RMC-6236) for people with advanced non-small cell lung cancer that has a specific RAS mutation. It's for those who have already tried 1 or 2 previous treatments, including immunotherapy and chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and agree to the study's rules.
- You have non-small cell lung cancer (NSCLC) that has spread or cannot be removed with surgery.
- Your tumor has a specific RAS mutation (in KRAS, NRAS, or HRAS at positions 12, 13, or 61).
- You have had 1 or 2 prior treatments, including an immunotherapy (like Keytruda or Opdivo) and chemotherapy (like carboplatin or cisplatin).
- You have not taken a direct RAS-targeting drug or docetaxel before.
- You can swallow pills and you do not have untreated brain metastases or serious heart, lung, or stomach issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called RMC-5127 for people with advanced solid tumors that have a specific KRAS G12V mutation. The study aims to see if this targeted therapy can help when other treatments have stopped working or caused side effects.
This trial tests whether adding a new drug (zoldonrasib) to standard chemotherapy and immunotherapy can help people with a specific type of lung cancer. It is for those with a RAS G12D mutation and no prior treatment for metastatic disease.
This study tests a new pill (GFH375) against a standard chemotherapy (docetaxel) for advanced lung cancer with a specific KRAS G12D mutation. If you have already tried platinum chemo and an immunotherapy, this trial might offer a new option.
This trial tests new drugs called RAS(ON) inhibitors combined with ivonescimab for people with solid tumors that have a RAS mutation. It aims to see if this combination can shrink tumors or slow their growth.
This study tests a new targeted pill (JMKX001899) against a standard chemotherapy drug (docetaxel) for people whose non-small cell lung cancer has a specific gene change called KRAS G12C and has already been treated with chemo and immunotherapy. The goal is to see if the new pill slows the cancer better or has fewer side effects.
This study tests a new pill called Daraxonrasib that targets cancers with a specific KRAS mutation. It is for people with advanced bile duct cancer that has grown after at least one prior treatment, to see if it can shrink the cancer or slow its growth.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.